Press Releases
- Active Biotech: Notice of Annual General Meeting of Shareholders April 11, 2012 08:30 (CEST)
- Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients March 15, 2012 13:00 (CET)
- Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress February 24, 2012 08:30 (CET)
- Year-end Report January - December 2011 February 16, 2012 08:30 (CET)
- Active Biotech's Prostate Cancer Project TASQ in Phase I Combination Therapy Trial January 23, 2012 08:30 (CET)
- Active Biotech to Present at the JP Morgan 30th Annual Healthcare Conference January 4, 2012 08:30 (CET)
- Active Biotech's election committee appointed November 10, 2011 16:00 (CET)
- Active Biotech AB Interim Report January - September 2011 November 3, 2011 08:30 (CET)
- Information regarding Active Biotech's candidate drug laquinimod November 2, 2011 15:18 (CET)
- INVESTIGATIONAL LAQUINIMOD DEMONSTRATES ITS POTENTIAL AS A NEW ORAL TREATMENT FOR RRMS October 19, 2011 08:30 (CEST)